Prevalence of Covid-19 Symptoms Among Inflammatory Bowel Disease Patients Treated with Biological Agents.

Conley, Thomas E; Probert, Chris; Subramanian, Sreedhar

Conley, Thomas E; Probert, Chris; Subramanian, Sreedhar.

Conley TE; Department of Gastroenterology, Liverpool University Foundation Hospitals NHS Trust, Liverpool, UK.
Probert C; Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool, UK.
Subramanian S; Department of Gastroenterology, Liverpool University Foundation Hospitals NHS Trust, Liverpool, UK.

J Crohns Colitis ; 14(12): 1794-1795, 2020 Dec 02.

Article in English | MEDLINE | ID: covidwho-756893

Subject(s)

Biological Factors/therapeutic use; COVID-19/etiology; Immunomodulating Agents/therapeutic use; Inflammatory Bowel Diseases/drug therapy; Adolescent; Adult; Aged; Aged, 80 and over; COVID-19/diagnosis; COVID-19/epidemiology; COVID-19/prevention & control; Female; Humans; Inflammatory Bowel Diseases/complications; Inflammatory Bowel Diseases/immunology; Male; Middle Aged; Patient Acuity; Prevalence; Risk Factors; Self Report; Young Adult

Keywords

Covid-19; Inflammatory bowel disease; biologics

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Biological Factors / COVID-19 / Immunomodulating Agents Type of study: Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: J Crohns Colitis Journal subject: Gastroenterology Year: 2020 Document Type: Article Affiliation country: Ecco-jcc

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google